Princeton, New Jersey - Diligent Pharma, a leading provider of cloud-based solutions for connecting clinical research sponsors, contract research organizations (CROs), and technology/service providers, announced today the successful completion of its Series A funding round, raising a total of $8,270,000. The investment was led by PJC, a prominent venture capital firm, with participation from FCA Venture Partners.

Founded by Patricia Leuchten, Diligent Pharma has quickly established itself as a key player in the pharmaceutical manufacturing industry. The company's innovative approach revolutionizes the process of connecting clinical research sponsors with industry suppliers, significantly reducing the time required to initiate clinical trials by up to 70 days.

Diligent Pharma's flagship product, the Diligent Qualification Platform, is a cloud-based solution that encompasses a comprehensive database of Request For Information (RFI) details from industry suppliers worldwide. Additionally, the platform includes Vendor Qualification Assessments (VQAs) that are rigorously audited against the latest industry standards.

"Diligent Pharma is committed to transforming the way clinical research sponsors and industry suppliers connect," said Patricia Leuchten, Founder of Diligent Pharma. "This successful funding round will enable us to further enhance our platform and expand our reach, ultimately accelerating the pace of clinical trials and driving advancements in the pharmaceutical industry."